Seizures – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Seizures Market Outlook

Thelansis’s “Seizures Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Seizures treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Seizures Overview

Seizures can manifest as either provoked or unprovoked occurrences. Provoked seizures, also referred to as acute symptomatic seizures, can be triggered by various factors such as electrolyte disorders, toxins, head injuries, infectious processes, vascular anomalies, tumors, and other mass lesions. The causes of provoked seizures encompass complications associated with nearly any disease process. Common triggers include electrolyte disturbances (hypoglycemia, hyponatremia, hypernatremia, hypocalcemia, among others), acute toxic effects (antidepressants and sympathomimetics), withdrawal syndromes (ethanol and benzodiazepines), irregularities with prescribed antiepileptic medications, sepsis, CNS infections, hypoxic brain injury, traumatic brain injury, stroke (ischemic or hemorrhagic), neoplasms, inflammatory conditions (lupus cerebritis and anti-NMDA receptor encephalitis), fever, and sleep deprivation. Seizures are categorized broadly into focal and generalized seizures, each containing various subtypes. Focal seizures originate in a specific part of the brain, with approximately 60% of individuals with epilepsy experiencing this type. The characterization of these seizures often reflects the brain region involved. On the other hand, generalized seizures result from abnormal neuronal activity rapidly affecting both sides of the brain. They may lead to loss of consciousness, falls, or extensive muscle contractions. Types of generalized seizures and their effects include:

• Absence seizures, characterized by appearing to stare into space with or without slight muscle twitching.
• Tonic seizures, causing stiffening of muscles, primarily in the back, legs, and arms.
• Clonic seizures, featuring repeated muscle jerking movements on both sides of the body.
• Myoclonic seizures, inducing jerks or twitches of the upper body, arms, or legs.
• Atonic seizures, resulting in a loss of normal muscle tone, potentially leading to falls or involuntary head dropping.
• Tonic-clonic seizures, a combination of symptoms involving body stiffening, repeated jerks of the arms and legs, and loss of consciousness.
• Secondary generalized seizures, which initiate in one part of the brain and then spread to both halves (essentially, a focal seizure followed by a generalized seizure).

Benzodiazepines like diazepam, midazolam, or lorazepam are considered first-line medications for ongoing seizures. The prognosis of patients with seizures depends mainly on any underlying causes. Those with seizures stemming from remediable medical or toxicologic issues tend to fare well with appropriate management. In contrast, patients with neoplastic causes or hypoxic brain injury generally have a poorer prognosis compared to those with metabolic causes. The prognosis for an individual experiencing a single unprovoked seizure depends on the absence of an established cause after clinical evaluation.

• Approximately 1 in 100 individuals in the United States has experienced either a single unprovoked seizure or has received a diagnosis of epilepsy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: